Une étude comparant Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab et Elotuzumab, Pomalidomide et Dexaméthasone ou Pomalidomide, Bortézomib et Dexaméthasone chez des participants atteints de myélome en rechute ou réfractaire qui ont reçu un anticorps anti-CD38 et du lénalidomide (MonumenTAL-6)
Une étude randomisée de phase 3 comparant le talquetamab en association avec le pomalidomide (Tal-P), le talquetamab en association avec le teclistamab (Tal-Tec) et le choix de l'investigateur entre l'élotuzumab, le pomalidomide et la dexaméthasone (EPd) ou le pomalidomide, le bortézomib et la dexaméthasone ( PVd) chez les participants atteints d'un myélome en rechute ou réfractaire qui ont reçu 1 à 4 lignes de traitement antérieures, y compris un anticorps anti-CD38 et du lénalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Augsburg, Allemagne, 86156
- Klinikum Augsburg
-
Halle, Allemagne, 06120
- Universitaetsklinikum Halle Saale
-
Heidelberg, Allemagne, 69120
- Universitaetsklinikum Heidelberg
-
Magdeburg, Allemagne, 39120
- Universitaetsklinikum Magdeburg A.oe.R
-
München, Allemagne, 81675
- Klinikum rechts der Isar der TU Muenchen
-
Tübingen, Allemagne, 72076
- Universitaetsklinikum Tuebingen
-
Würzburg, Allemagne, 97080
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Riyadh, Arabie Saoudite, 11564
- King Faisal Specialist Hospital & Research Center
-
Riyadh, Arabie Saoudite, 12231
- King Fahad Medical City
-
Riyadh, Arabie Saoudite, 11481
- King Abdullah International Medical Research Center (KAIMRC)
-
-
-
-
-
Buenos Aires, Argentine, C1280AEB
- Hospital Britanico de Buenos Aires
-
Buenos Aires, Argentine, C1114AAN
- Fundaleu
-
CABA, Argentine, C1118AAT
- Hospital Aleman
-
-
-
-
-
Adelaide, Australie, 5000
- Royal Adelaide Hospital
-
Box Hill, Australie, 3128
- Box Hill Hospital
-
Darlinghurst, Australie, 2010
- St Vincents Hospital
-
Fitzroy, Australie, 3065
- St Vincents Hospital Melbourne
-
Southport, Australie, 4215
- Gold Coast University Hospital
-
West Perth, Australie, 6005
- Perth Blood Institute
-
Wollongong, Australie, 2500
- Wollongong Hospital
-
-
-
-
-
Charleroi, Belgique, 6060
- Grand Hopital De Charleroi Site Les Viviers
-
Genk, Belgique, 3600
- Ziekenhuis Oost-Limburg
-
Ghent, Belgique, 9000
- Ghent University Hospital
-
Sint-Niklaas, Belgique, 9100
- AZ Nikolaas - Campus Sint-Niklaas Moerland
-
-
-
-
-
Belo Horizonte, Brésil, 30110-022
- Cetus Oncologia
-
Brasília, Brésil, 70390 700
- IDOR - Regional Brasilia
-
Caxias do Sul, Brésil, 95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba, Brésil, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Porto Alegre, Brésil, 90035-903
- Hospital De Clinicas De Porto Alegre
-
Recife, Brésil, 50070-480
- IDOR - Regional Pernambuco
-
Rio de Janeiro, Brésil, 22793-080
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador, Brésil, 41253-190
- IDOR - Regional Bahia
-
São José do Rio Preto, Brésil, 15090-000
- Funfarme Sjrp
-
São Paulo, Brésil, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brésil, 04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo, Brésil, 01323 001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
São Paulo, Brésil, 01401 002
- IDOR - Regional Sao Paulo
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z4E6
- British Columbia Cancer Agency
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V5C2
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M5G2M9
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
Beijing, Chine, 100034
- Peking University First Hospital
-
Beijing, Chine, 100020
- Beijing Chaoyang Hospital
-
Beijing, Chine, 101199
- Peking University People's Hospital
-
Changsha, Chine, 410011
- The Second Xiangya Hospital of Central South Hospital
-
Changzhou, Chine, 213000
- Changzhou No 2 Peoples Hospital
-
Chengdu, Chine, 610032
- Sichuan Provincial Peoples Hospital
-
Fuzhou, Chine, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Fuzhou, Chine, 350001
- Fujian Meidical University Union Hospital
-
Guangzhou, Chine, 510515
- Nanfang Hospital of Southern Medical Hospital
-
Guangzhou, Chine, 510060
- Sun Yat Sen University Cancer Center
-
Hangzhou, Chine, 310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine
-
Hangzhou, Chine, 310003
- First hospital affiliated of Zhejiang Medical university
-
Hohhot, Chine, 010051
- The Affiliated Hospital of Inner Mongolia Medical College
-
Jinan, Chine, 250012
- Qilu Hospital of Shandong University
-
Nanchang, Chine, 330006
- The First Affiliated Hospital of NanChang University
-
Nanjing, Chine, 210008
- Nanjing Drum Tower Hospital
-
Nanning, Chine, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
Shanghai, Chine, 200025
- Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
-
Shanghai, Chine, 200065
- Tongji Hospital of Tongji University
-
Shanghai, Chine, 200434
- Shanghai Fourth People s Hospital
-
Shenyang, Chine, 110055
- Shengjing Hospital Of China Medical University
-
Shenzhen, Chine, 518036
- Peking University Shenzhen Hospital
-
Taiyuan, Chine, 030032
- Shanxi Bethune Hospital
-
Tianjin, Chine, 30060
- Tianjin Medical University Cancer Institute and Hospital
-
Wenzhou, Chine, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Chine, 430030
- Tongji Hospital, Tongji Medical College of HUST
-
Xi'an, Chine, 710004
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xiamen, Chine, 361026
- The first affiliated hospital of xiamen university
-
-
-
-
-
Busan, Corée du Sud, 49201
- Dong-A University Hospital
-
Busan, Corée du Sud, 49241
- Pusan National University Hospital
-
Jeollanam-do, Corée du Sud, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, Corée du Sud, 03080
- Seoul National University Hospital
-
Seoul, Corée du Sud, 06351
- Samsung Medical Center
-
Seoul, Corée du Sud, 06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
Ulsan, Corée du Sud, 44033
- Ulsan University Hospital
-
-
-
-
-
Aarhus, Danemark, 8200
- Aarhus University Hospital
-
Odense C, Danemark, 5000
- Odense University Hospital
-
Vejle, Danemark, 7100
- Vejle Hospital
-
-
-
-
-
Asturias, Espagne, 33394
- Hosp. de Cabuenes
-
Barcelona, Espagne, 08035
- Hosp Univ Vall D Hebron
-
Burgos, Espagne, 09003
- Hosp. Univ. de Burgos
-
Cáceres, Espagne, 10003
- Hosp. San Pedro de Alcantara
-
Donostia / San Sebastian, Espagne, 20014
- Hosp. Univ. Donostia
-
Granada, Espagne, 18014
- Hosp. Univ. Virgen de Las Nieves
-
Lugo, Espagne, 27003
- Hosp. Univ. Lucus Augusti
-
Madrid, Espagne, 28046
- Hosp. Univ. La Paz
-
Palma de Mallorca, Espagne, 07120
- Hosp. Univ. Son Espases
-
Pamplona, Espagne, 31008
- Clinica Univ. de Navarra
-
Pamplona, Espagne, 31008
- Complejo Hosp de Navarra - Hosp de Navarra
-
Salamanca, Espagne, 37007
- Hosp Clinico Univ de Salamanca
-
Santander, Espagne, 39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela, Espagne, 15706
- Hosp. Clinico Univ. de Santiago
-
-
-
-
-
Lille, France, 59000
- Hopital Claude Huriez
-
Limoges, France, 87042
- CHU de Limoges Hopital Dupuytren
-
Lyon, France, 69002
- Hospices Civils de Lyon HCL
-
Marseille, France, 13009
- Institut Paoli Calmettes
-
Nantes, France, 44093
- CHU Nantes
-
Paris, France, 75010
- Hopital Saint Louis
-
Pessac, France, 33604
- CHU de Bordeaux - Hospital Haut-Leveque
-
Strasbourg, France, 67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse, France, 31100
- Institut Universitaire du Cancer Toulouse Oncopole
-
Tours, France, 37044
- CHRU Tours Hopital Bretonneau
-
-
-
-
-
Athens, Grèce, 115 28
- Alexandra General Hospital of Athens
-
Athens, Grèce, 115 25
- 251 Airforces Hospital
-
Thessaloniki, Grèce, 546 39
- Theageneio Cancer Hospital
-
-
-
-
-
Budapest, Hongrie, 1088
- Semmelweis Egyetem, Belgyogyaszati es Hematologiai Klinika
-
Budapest, Hongrie, 1097
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Debrecen, Hongrie, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Nyíregyháza, Hongrie, 4400
- Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
-
Pécs, Hongrie, 7624
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
-
-
-
-
Gūrgaon, Inde, 122002
- Fortis Memorial Research Institute
-
Lucknow, Inde, 226014
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
-
Pune, Inde, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
-
-
-
-
Be’er Ya‘aqov, Israël, 70300
- Shamir Medical Center Assaf Harofeh
-
Haifa, Israël, 3436212
- Carmel Medical Center
-
Petah Tikva, Israël, 49100
- Rabin Medical center - Petah-Tikva
-
Ramat Gan, Israël, 52621
- Sheba Medical Center
-
Tel Aviv, Israël, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Alessandria, Italie, 15121
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
-
Bologna, Italie, 40138
- A O U Sant Orsola Malpighi
-
Brindisi, Italie, 72100
- Ospedale Perrino
-
Catania, Italie, 95122
- ARNAS Garibaldi P O Nesima
-
Genova, Italie, 16132
- Ospedale Policlinico San Martino IRCCS
-
Legnano, Italie, 20025
- Asst Ovest Milanese - Ospedale Di Legnano
-
Milan, Italie, 20132
- IRCCS Ospedale San Raffaele
-
Milan, Italie, 20122
- Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
-
Pavia, Italie, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Pescara, Italie, 65124
- Presidio Ospedaliero Pescara
-
Ravenna, Italie, 48121
- Ospedale S. Maria Delle Croci
-
Torino, Italie, 10126
- Oncologia Medica-Città Della Salute E Della Scienza Di Torino
-
Verona, Italie, 37134
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Bunkyō City, Japon, 113 8431
- Juntendo University Hospital
-
Fukuoka, Japon, 814-0180
- Fukuoka University Hospital
-
Hamamatsu, Japon, 431 3192
- Hamamatsu University Hospital
-
Kanazawa, Japon, 920 8641
- Kanazawa University Hospital
-
Kyoto, Japon, 602-8566
- University Hospital Kyoto Prefectural University of Medicine
-
Nagasaki, Japon, 856-8562
- National Hospital Organization Nagasaki Medical Center
-
Narita, Japon, 286-8523
- Japanese Red Cross Narita Hospital
-
Niigata, Japon, 951-8566
- Niigata Cancer Center Hospital
-
Nishinomiya Shi, Japon, 663 8501
- Hyogo Medical University Hospital
-
Osaka, Japon, 543-8555
- Japanese Red Cross Osaka Hospital
-
Sapporo, Japon, 060-8604
- Sapporo City General Hospital
-
Sendai, Japon, 980 8574
- Tohoku University Hospital
-
Shibuya-ku, Japon, 150-8935
- Japanese Red Cross Medical Center
-
Shiwa-gun, Japon, 028-3695
- Iwate Medical University Hospital
-
Suita, Japon, 565 0871
- The University of Osaka Hospital
-
Sunto Gun, Japon, 411 8777
- Shizuoka Cancer Center
-
Tokyo, Japon, 135 8550
- The Cancer Institute Hospital of JFCR
-
Tottori, Japon, 683-0824
- Tottori University Hospital
-
Tsukuba, Japon, 305 8576
- University of Tsukuba Hospital
-
Yokohama, Japon, 241 8515
- Kanagawa Cancer Center
-
-
-
-
-
Salzburg, L'Autriche, 05020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, L'Autriche, 1160
- Klinik Ottakring
-
Vienna, L'Autriche, A-1090
- Medical University Vienna MUV
-
-
-
-
-
Guadalajara, Mexique, 45645
- Centro de Quimioterapia e Investigacion
-
Huixquilucan, Mexique, 52787
- Hematologica Alta Especialidad
-
Monterrey, Mexique, 64460
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
-
-
-
-
Almere Stad, Pays-Bas, 1315RA
- Flevoziekenhuis
-
Eindhoven, Pays-Bas, 5623 EJ
- Catharinaziekenhuis
-
Nieuwegein, Pays-Bas, 3435 CM
- St. Antonius Ziekenhuis Nieuwegein
-
The Hague, Pays-Bas, 2545 CH
- Haga ziekenhuis
-
Zwolle, Pays-Bas, 8025 AB
- Isala Kliniek
-
-
-
-
-
Biała Podlaska, Pologne, 21 500
- Wojewodzki Szpital Specjalistyczny
-
Brzozów, Pologne, 36-200
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Kielce, Pologne, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Lublin, Pologne, 20-090
- Centrum Onkologii Ziemii Lubelskiej
-
Szczecin, Pologne, 71-252
- Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
-
Wroclaw, Pologne, 50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Blackpool, Royaume-Uni, FY3 8NR
- Blackpool Victoria Hospital
-
Cardiff, Royaume-Uni, CF14 4HY
- University Hospital of Wales
-
Dundee, Royaume-Uni, DD1 9SY
- Ninewells Hospital
-
Leeds, Royaume-Uni, LS9 7TF
- St James University Hospital
-
London, Royaume-Uni, SE5 9RS
- Kings College Hospital
-
Nottingham, Royaume-Uni, NG5 1PB
- Nottingham City Hospital
-
Plymouth, Royaume-Uni, PL6 8DH
- University Hospitals Plymouth NHS Trust
-
Portsmouth, Royaume-Uni, PO6 3LY
- Queen Alexandra Hospital
-
-
-
-
-
Lund, Suède, 221 85
- Skanes universitetssjukhus
-
Umeå, Suède, 901 85
- Norrlands Universitetssjukhus
-
Uppsala, Suède, 75185
- Akademiska Sjukhuset
-
Varberg, Suède, 432 81
- Varberg Hospital
-
-
-
-
-
Brno-Bohunice, Tchéquie, 625 00
- Fakultni nemocnice Brno
-
Hradec Králové, Tchéquie, 500 05
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tchéquie, 779 00
- University Hospital Olomouc
-
Ostrava, Tchéquie, 708 52
- Fakultni Nemocnice Ostrava
-
-
-
-
-
Ankara, Turquie (Türkiye), 06680
- Liv Hospital Ankara
-
Ankara, Turquie (Türkiye), 06620
- Ankara Universitesi Tip Fakultesi Cebeci Arastirma ve Uygulama Hastanesi
-
Denizli, Turquie (Türkiye), 20070
- Pamukkale Universitesi Tip Fakultesi
-
Istanbul, Turquie (Türkiye), 34214
- Medipol University Hospital
-
Samsun, Turquie (Türkiye), 55200
- Ondokuz Mayis Universitesi Saglik Uygulama ve Arastirma Merkezi
-
-
-
-
California
-
Clovis, California, États-Unis, 93611
- UCSF Fresno
-
Santa Monica, California, États-Unis, 90404
- UCLA
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06519
- Yale University School Of Medicine
-
-
Delaware
-
Newark, Delaware, États-Unis, 19713
- Medical Oncology Hematology Consultants, PA
-
-
Florida
-
Hollywood, Florida, États-Unis, 33021
- Memorial Healthcare System
-
Tampa, Florida, États-Unis, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Winship Cancer Institute Emory University
-
Newnan, Georgia, États-Unis, 30265
- City of Hope Cancer Center
-
-
Idaho
-
Coeur d'Alene, Idaho, États-Unis, 83814
- Kootenai Health
-
-
Illinois
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center
-
-
Iowa
-
Waukee, Iowa, États-Unis, 50263
- University of Iowa Health Care
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40207
- Norton Cancer Institute
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70808
- Our Lady of the Lake Hospital
-
-
Maryland
-
Annapolis, Maryland, États-Unis, 21401
- Luminis Health Center for Cancer and Blood Disorders
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland School of Medicine
-
Baltimore, Maryland, États-Unis, 21287
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Cancer Institute
-
Southfield, Michigan, États-Unis, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University Of Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic Rochester
-
Saint Paul, Minnesota, États-Unis, 55101
- Regions Hospital
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68105
- University of Nebraska
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, États-Unis, 14263
- Roswell Park Cancer Institute
-
New York, New York, États-Unis, 10065
- Weill Cornell Medical College
-
Syracuse, New York, États-Unis, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27705
- Duke University Medical Center
-
-
Ohio
-
Canton, Ohio, États-Unis, 44718
- Gabrail Cancer Center
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic
-
Cleveland, Ohio, États-Unis, 44106
- Louis Stokes Cleveland VA Med Ctr
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health And Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State Milton S Hershey Medical Ctr
-
Philadelphia, Pennsylvania, États-Unis, 19107 4215
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425-8900
- Medical University of South Carolina
-
Greenville, South Carolina, États-Unis, 29607
- Bon Secours Saint Francis Cancer Center
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern Parkland Hospital
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern
-
Houston, Texas, États-Unis, 77030
- Houston Methodist Neal Cancer Center at Texas Medical Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- University of Virginia
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, États-Unis, 98104
- Swedish Cancer Institute
-
Tacoma, Washington, États-Unis, 98405
- NorthWest Medical Specialties, PLLC
-
-
Wisconsin
-
La Crosse, Wisconsin, États-Unis, 54601
- Gundersen Health System
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College Of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Documented multiple myeloma as defined by the criteria below: (a) multiple myeloma diagnosis according to the international myeloma working group (IMWG) diagnostic criteria (b) measurable disease at screening as assessed by central laboratory, defined by any of the following: (i) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or (ii) urine M-protein level >= 200 milligram (mg) per 24 hours; or (iii) light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Relapsed or refractory disease as defined below: a) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by IMWG criteria greater than (>) 60 days after cessation of treatment. b) Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or confirmed PD by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Documented evidence of PD or failure to achieve a minimal response to the last line of therapy based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
Exclusion Criteria:
- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients
- Stroke, transient ischemic attack, or seizure within 6 months prior to signing informed consent form (ICF)
- Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
- A maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14-day period before the first dose of study drug
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm A: Talquetamab + Pomalidomide (Tal-P)
Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. |
Pomalidomide will be administered orally.
Autres noms:
Dexamethasone will be administered either orally or intravenously. Talquetamab will be administered as a SC injection.
Autres noms:
|
|
Expérimental: Arm B: Talquetamab + Teclistamab (Tal-Tec)
Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. |
Teclistamab will be administered as a SC injection.
Autres noms:
Dexamethasone will be administered either orally or intravenously. Talquetamab will be administered as a SC injection.
Autres noms:
|
|
Comparateur actif: Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)
Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication. |
Pomalidomide will be administered orally.
Autres noms:
Dexamethasone will be administered either orally or intravenously. Elotuzumab will be administered intravenously.
Autres noms:
Bortezomib will be administered as a SC injection.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression Free Survival (PFS)
Délai: Up to 3 years 5 months
|
PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first. |
Up to 3 years 5 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Response Rate (ORR)
Délai: Up to 3 years 5 months
|
ORR is defined as the percentage of participants with best overall response of partial response (PR) or better according to international myeloma working group (IMWG) response criteria. |
Up to 3 years 5 months
|
|
Complete Response (CR) or Better Rate
Délai: Up to 3 years 5 months
|
CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria. |
Up to 3 years 5 months
|
|
Very Good Partial Response (VGPR) or Better Rate
Délai: Up to 3 years 5 months
|
VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria. |
Up to 3 years 5 months
|
|
Minimal Residual Disease (MRD)-negative CR Rate
Délai: Up to 3 years 5 months
|
MRD-negative CR is defined as the percentage of participants who achieve both CR or better and MRD negativity at a threshold of 10^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy (SST). |
Up to 3 years 5 months
|
|
Overall Survival (OS)
Délai: Up to 3 years 5 months
|
OS is defined as the time from randomization to the date of participant's death. |
Up to 3 years 5 months
|
|
Progression Free Survival on Next-line Therapy (PFS2)
Délai: Up to 3 years 5 months
|
PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first. |
Up to 3 years 5 months
|
|
Time to Next Treatment (TTNT)
Délai: Up to 3 years 5 months
|
TTNT is defined as the time from randomization to the start of SST. |
Up to 3 years 5 months
|
|
Serum Concentration of Talquetamab and Teclistamab
Délai: Up to 3 years 5 months
|
Serum concentration of talquetamab and teclistamab will be reported. |
Up to 3 years 5 months
|
|
Number of Participants with Anti-drug Antibodies (ADAs) to Talquetamab and Teclistamab
Délai: Up to 3 years 5 months
|
Number of participants with ADAs to talquetamab and teclistamab will be reported. |
Up to 3 years 5 months
|
|
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
Délai: Up to 3 years 5 months
|
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale. |
Up to 3 years 5 months
|
|
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EORTC-QLQ-C30
Délai: Up to 3 years 5 months
|
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. |
Up to 3 years 5 months
|
|
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Délai: Up to 3 years 5 months
|
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Up to 3 years 5 months
|
|
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Patient Global Impression -Severity (PGI-S)
Délai: Up to 3 years 5 months
|
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and EORTC-QLQ-C30 in this population. The response options are presented as a 5-point verbal rating scale from "none" to "very severe." |
Up to 3 years 5 months
|
|
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Epstein Taste Survey
Délai: Up to 3 years 5 months
|
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The epstein taste survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes developed for use in patients with head and neck cancer as a composite of the Vanderbilt Head and Neck Symptom Survey. |
Up to 3 years 5 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by MySIm-Q
Délai: Up to 3 years 5 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale. |
Up to 3 years 5 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EORTC-QLQ-C30
Délai: Up to 3 years 5 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high or healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale or item represents a high level of symptomatology or problems. |
Up to 3 years 5 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EQ-5D-5L
Délai: Up to 3 years 5 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Up to 3 years 5 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by PGI-S
Délai: Up to 3 years 5 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by PGI-S will be reported. The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and EORTC-QLQ-C30 in this population. The response options are presented as a 5-point verbal rating scale from "none" to "very severe." |
Up to 3 years 5 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Epstein Taste Survey
Délai: Up to 3 years 5 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by epstein taste survey will be reported. The epstein taste survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes. developed for use in patients with head and neck cancer as a composite of the Vanderbilt Head and Neck Symptom Survey. |
Up to 3 years 5 months
|
|
Percentage of Participants With Meaningful Improvement in HRQoL as Assessed by EORTC-QLQ-C30
Délai: Up to 3 years 5 months
|
Percentage of participants with meaningful improvement in HRQol as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high or healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale or item represents a high level of symptomatology or problems. |
Up to 3 years 5 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
Délai: Up to 3 years 5 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to 3 years 5 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Myélome multiple
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés polycycliques
- Produits chimiques inorganiques
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Stéroïdes, fluorés
- Grossissement
- Acides boroniques
- Acides, non carboxylique
- Acides
- Composés de bore
- Pyrazines
- Bortézomib
- Dexaméthasone
- pomalidomide
- élotuzumab
- talquetamab
Autres numéros d'identification d'étude
- 64407564MMY3009
- 64407564MMY3009 (Autre identifiant: Janssen Research & Development, LLC)
- 2022-502446-27-00 (Identificateur de registre: EUCT number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .